 |
|
Patient Priority: Trusted Treatment |
|
| Proven Class III Mid-potency Safety |
- Safety profile comparable to other forms of betamethasone valerate1,2
- LUXÍQ® (betamethasone valerate) Foam 0.12% showed no evidence of inducing adrenal suppression1,2
- 18 adult patients with psoriasis or atopic dermatitis affecting at least 30% of their body applied 15g of either LUXÍQ® Foam or betamethasone valerate ointment twice daily for 7 days1,2
|
| Safe and Well Tolerated |
- The most frequent side effects associated with the use of LUXÍQ® Foam are mild and transient burning, stinging, or itching at the application site
|
|
- LUXÍQ® Foam is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp, such as psoriasis, eczema, and seborrheic dermatitis.
|
|
References: 1. LUXÍQ® Foam NDA. 2. Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38:628-632.
|
